Preclinical evaluation of diethoxy-(1-phenyl-1,3-butanedionato) titanium (IV) in human tumour xenografts.
The antitumour activity of diethoxy-(1-phenyl-1,3-butanedionato)titanium (IV) (DBT) in comparison to cis-dichlorodiammine platinum (cisplatin, cis-DDP) and cyclophosphamide (CTX) against human breast, colo-rectal and lung tumour lines growing as xenografts in nude mice was investigated. The antitumour activities and toxicities of DBT and cis-DDP are comparable whereas CTX was the most effective agent.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014025:Titanium / Q000009:adverse effects / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D003520:Cyclophosphamide; D014025:Titanium; C043899:diethoxy-(1-phenyl-1,3-butanedionato)titanium (IV); D002945:Cisplatin